INTRODUCTION
Breast cancer is the most dreadful cancer for the women in the United States, and has become the most prevalent cancer in women even in the Asian countries.(1) Before the introduction of the concept of the breast conservation, more radical operations such as radical or modified radical mastectomy had been used for the most of the breast cancer patients. After the incorporation of the breast-conserving operation into the armamentarium of the therapeutic modalities against the breast cancer after becoming to get the widespread approval as a standard cancer treatment, the need of the external radiation therapy for the breast remained after the lumpectomy has been increasing. (2) In addition, many of the metastatic foci from the index tumor should be considered as the therapeutic targets for the radiation. that is integrated in the prostaglandin E 2 (PGE2) synthesis, Purpose: Celecoxib and Ad-mda7 have shown its ability to enhance radiosensitivity in various cancer cells in vitro. We expected to synergistically enhance radiosensitivity by combing celecoxib and Ad-mda7 in breast cancer cells in vitro. Methods: MDA-MB-436 and MDA-MB-468 human breast cancer cells were exposed to different doses (0, 2, 4, and 6 Gy) of radiation with or without pretreatment with either Ad-mda7 or celecoxib alone, or with the combination for three days prior to irradiation. Clonogenic cell survival assay was used to compare the radiosensitizing effect. Fluorescence activated cell sorting analysis was performed to assess cell cycle changes and the subdiploid cell population. We determined the prostaglandin E2 (PGE2) concentration before and after the irradiation (2 Gy, 24 hours). We performed western blot analysis of Akt, phosphorylated Akt, β -catenin, and cyclooxygenase-2 (COX-2). Results: At the sublethal dose of celecoxib and Ad-mda7, the combination showed significantly enhanced radiosensitivity. The enhancement factor for the combination treatment was 1.44 in MDA-MB-468 cells and 1.75 in MDA-MB-436 cells. There were an increased percentage of apoptotic cells in the combination therapy group as compared to the controls, but this was not statistically significant. Cell cycle analysis demonstrated an increase in the G2/M phase of the cell cycle in the combination group compared with controls. The concentration of PGE2 was significantly decreased after the irradiation in both cell lines compared to the controls. Western blot analysis confirmed that this combination treatment effectively suppress the expression of Akt, phosphorylated Akt, and COX-2 in those cell lines, except β -catenin. Conclusion: Cotreatment of Ad-mda7 plus celecoxib definitely showed radioenhancing effect. We presumed that this effect may be the arrest of the cells at the radiosensitive G2/M phase of the cell cycle. 
METHODS

Cell lines
The estrogen receptor negative and HER2/neu negative MDA-MB-436 and MDA-MB-468 human breast cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, USA). The cells were maintained in high glucose Dulbecco' s modified Eagle medium/ F-12 media supplemented with 10% fetal bovine serum with 10 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μ g/mL streptomycin (GIBCO Invitrogen Co., Grand Island, USA) in a humidified 37℃, 5% CO2 atmosphere. (6) Adenovirus transduction and celecoxib treatment The doses of vector and celecoxib were selected to ensure toxicity of less than 50% to compare the combinatorial effect of Ad-mda7 and celecoxib.
Clonogenic cell survival assay (CSA)
Clonogenic survival assay was applied to determine whether celecoxib and Ad-mda7 or both enhance radiosensitivity of the MDA-MB-436 and MDA-MB-468 human breast cancer cells in vitro. Cells in culture were treated with celecoxib, Ad-mda7 or both for 3 days, which were then to be irradiated with different level of doses (0, 2, 4 ,6 Gy) of γ -rays using a 137 Cs source (3.7 Gy/min). The cells were assayed for colony-forming ability by plating them again in predetermined certain cellular numbers into 100-mm dishes in the unconditioned media afterwards. On completion of 14 day incubation, the cells were stained with 0.5% crystal violet in absolute ethanol to make all the colonies to be seen clearly, and colonies with more than 50 cells predetermined under the light microscope were counted manually. Survival curves after the radiation following each treatment including control were outlined after calibrating for the toxicity produced by celecoxib, Ad-mda7, or both. Clonogenic survival curves were generated from three independent experiments by taking the average survival levels using least-squares regression by the linear-quadratic model. (9) Fluorescence activated cell sorting (FACS) and cell cycle analysis 
Statistical analysis
Statistical analysis was performed between control and treated groups and among the different experimental groups. Comparisons of means were carried out by using the paired t-test. The densitometry of the Western blots was also analyzed for significance by the paired t-test.
Differences with a value of p<0.05 were considered to be statistically significant. The significance of the results was determined by the paired t-test.
RESULTS
Enhanced expression of MDA7 protein after the combination of celecoxib and Ad-mda7
Unexpectedly, we got the increased MDA7 protein expression, confirmed by immunoblotting, after treating cells with celecoxib and Ad-mda7, compared to the either alone treatment ( Figure 1 ).
Increased efficacy of radiosensitization after celecoxib, Ad-mda7, or both At a radiation dose of around 2 Gy, shoulder formation easily seen in control could be eliminated after the combination pretreatment in advance to the radiation in both cell lines.
Flow cytometry and apoptosis
In MDA-MB-436 cells, we already proved that the combination treatment with celecoxib and Ad-mda7 was superior to the either alone treatment without additional radiation treatment (p=0.02 for celecoxib and p=0.08
for Ad-mda7) ( Figure 3) . (6) The apoptosis seemed to be increased more, after the combination treatment followed by radiation exposure, compare with celecoxib (p=0.05)
or Ad-mda7 (p=0.08). In MDA-MB-468 cells (Figure 4 ), the apoptosis seemed to be more robust in Ad-mda7 than celecoxib treatment before radiation (p=0.01). There was no significant difference between Ad-mda7 and the combination. After the radiation, the combination resulted in the most significant increase in the apoptosis compared with any other monotherapy (p=0.001 for celecoxib, p= 0.03 for Ad-mda7). And the Ad-mda7 had much influence on the apoptosis than celecoxib (p=0.001).
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We already showed that the combination treatment of Due to the fact that we couldn' t get the expression of COX-2 in the MDA-MB-468 cells after the radiation exposure even in the control group, we thought that radiation may markedly interfere the action of COX-2 through the unknown mechanism (Table 1) . Ad-mda7 and celecoxib should be explored later. And the radiation itself may induce some radioprotective mechanisms even after treatment, many more studies should be followed to clarify whole network to selectively enhance radiosensitivity without triggering antiapoptotic network.
Ad-mda7 and celecoxib combination decreases expression of COX-2, Akt, and p-Akt
CONCLUSION
In conclusion, the expression of MDA-7 increased sig- 
